<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05084573</url>
  </required_header>
  <id_info>
    <org_study_id>UW 20-247</org_study_id>
    <nct_id>NCT05084573</nct_id>
  </id_info>
  <brief_title>Continuous Interscalene Block vs Liposomal Bupivacaine After Proximal Humerus Fracture Surgery</brief_title>
  <acronym>CLIP-H</acronym>
  <official_title>Continuous Standard Bupivacaine Interscalene Block Versus Single Injection Liposomal Bupivacaine Following Surgical Fixation of Proximal Humerus Fractures</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Hong Kong</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The University of Hong Kong</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the efficacy of continuous interscalene block (CISB)&#xD;
      using standard bupivacaine versus a single interscalene injection of liposomal bupivacaine&#xD;
      (LB) on pain control following surgical fixation of proximal humerus fractures.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Restricted range of motion following open reduction and internal fixation (ORIF) of proximal&#xD;
      humerus fractures is a potential complication that severely limits functional outcomes . It&#xD;
      must therefore be avoided by adequate pain control in order to allow for early mobilisation&#xD;
      in addition to physiotherapy.&#xD;
&#xD;
      Interscalene block (ISB) is one of the most effective and widely used regional analgesic&#xD;
      options shoulder surgeries. ISB can be delivered as a single injection or by continuous&#xD;
      infusion via an indwelling catheter. While continuous interscalene block (CISB) offers a&#xD;
      longer duration of analgesia as compared to a single injection of the same anaesthetic, it&#xD;
      carries an inherent risk of catheter malposition, dislodgement, and infection.&#xD;
&#xD;
      As compared to standard bupivacaine (SB), liposomal bupivacaine (LB) is a formulation&#xD;
      designed to prolong the duration of analgesia up to 72 hours via a single injection. While&#xD;
      this could avoid the need for an indwelling catheter, results of studies comparing LB to CISB&#xD;
      have been inconsistent.&#xD;
&#xD;
      The purpose of this is non-inferiority trial is to compare the effectiveness of a single&#xD;
      injection of LB versus CISB with SB on pain control following ORIF of proximal humerus&#xD;
      fractures. The study hypothesis is that LB is not unacceptably worse than CISB with regard to&#xD;
      pain control in the first two postoperative days.&#xD;
&#xD;
      Patients providing informed consent will be screened for eligibility. All eligible patients&#xD;
      will be randomly assigned in a double-blind manner (participant and investigator) and a 1:1&#xD;
      ratio to receive either LB or CISB.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 1, 2020</start_date>
  <completion_date type="Anticipated">March 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Patients will be allocated to receive either continuous interscalene nerve block (CISB) using standard bupivacaine OR a single interscalene injection of liposomal bupivacaine (LB).</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
    <masking_description>Subjects, investigators, and all parties involved in patient management or data collection will be blinded throughout the study period.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Pain on movement as measured by Numerical Rating Scale (NRS)</measure>
    <time_frame>At each post-op day 1-7</time_frame>
    <description>Numerical rating scale (NRS) during attempted passive forward shoulder flexion to 90 degrees; 0 points (no pain) to 11 points (worst pain imaginable).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pain at rest as measured by Numerical Rating Scale (NRS)</measure>
    <time_frame>At each post-op day 1-7</time_frame>
    <description>Numerical rating scale (NRS) at rest; 0 points (no pain) to 11 points (worst pain imaginable).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Intraoperative opioid consumption</measure>
    <time_frame>Intraoperative</time_frame>
    <description>Intraoperative IV remifentanil consumption (mcg/kg/min)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of ISB related complications</measure>
    <time_frame>Intraoperative to post-op day 3</time_frame>
    <description>Complications related to interscalene block</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PCA morphine consumption</measure>
    <time_frame>From immediately post-operation to post-op day 2</time_frame>
    <description>Amount of patient-controlled analgesia (PCA) morphine consumed (mg)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with side effects effects of PCA using morphine</measure>
    <time_frame>From immediately post-operation to post-op day 2</time_frame>
    <description>Side effects related to opioid use (Nausea/Vomiting, Dizziness, Constipation)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rescue morphine consumption</measure>
    <time_frame>From immediately post-operation to post-op day 2</time_frame>
    <description>Additional opioid used in addition to PCA morphine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total length of stay</measure>
    <time_frame>Through study completion, an average of 1 year</time_frame>
    <description>Duration of hospital stay (days)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Analgesic consumption after discharge</measure>
    <time_frame>From post-op day 3 to day 7</time_frame>
    <description>Total analgesic consumption (dihydrocodeine) after hospital discharge (pill count)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Benefit of Analgesia Score (OBAS)</measure>
    <time_frame>Immediate post-operation to post-op day 3</time_frame>
    <description>Patient-reported measure of pain, side effects, and satisfaction of post-operative analgesia; 7 questions rated from 0 (worst outcome) to 4 (best outcome)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence of chronic pain at follow-up</measure>
    <time_frame>At 2 weeks, 6 weeks and 3 months post-op</time_frame>
    <description>Presence of chronic pain by self-report</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence of neuropathic pain at follow-up</measure>
    <time_frame>At post-op 2 weeks, 6 weeks and 3 months</time_frame>
    <description>Presence of neuropathic pain by physical examination and neuropathic pain questionnaire, a 10-item mixed self-report/observer rated physical exam measure ranging from 0 (no pain) to 10, with a score of 4 or greater diagnostic of neuropathic pain</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Region-specific physical functioning and symptoms</measure>
    <time_frame>At post-op 2 weeks, 6 weeks and 3 months</time_frame>
    <description>Physical function and symptoms measured by Shortened Disabilities of the Arm, Shoulder and Hand Questionnaire (QuickDASH), an 11-item patient-reported measure with a total score ranging from 0 (no disability) to 100 (most severe disability).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health-related quality of life (HRQOL)</measure>
    <time_frame>At post-op 2 weeks, 6 weeks and 3 months</time_frame>
    <description>12-item Short Form Health Survey (SF-12), a patient-reported outcome measure of HRQOL comprised of a mental component (MCS) and physical component (PCS), each with a final score ranging from 0 (worst outcome) to 100 (best outcome).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient satisfaction as measured by the Patient Satisfaction Questionnaire General Satisfaction Subscale</measure>
    <time_frame>At post-op 2 weeks, 6 weeks and 3 months</time_frame>
    <description>Patient satisfaction with healthcare provision as measured by the Patient Satisfaction Questionnaire General Satisfaction subscale (PSQ18-GS), a two-item subscale with a final score ranging from 0 (lowest satisfaction) to 10 (highest satisfaction)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">92</enrollment>
  <condition>Shoulder Fractures</condition>
  <arm_group>
    <arm_group_label>Liposomal bupivacaine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive a single bolus interscalene injection of 10mL 1.33% LB followed by placement of indwelling (sham) catheter in the interscalene region. Upon arrival in the recovery room, a nurse will connect the catheter to a fixed-rate portable elastometric pump (Easypump®, B Braun, Germany) filled with 300mL normal saline (NS) at a default fixed rate of infusion of 5mL/hr. The syringe, catheter, pump and clamp will be covered by opaque black bags to conceal the milky appearance of LB. The catheter will be removed on postoperative day 2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard bupivacaine CISB</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will receive a single bolus interscalene injection of 10mL 0.25% SB followed by placement of indwelling (sham) catheter in the interscalene region. Upon arrival in the recovery room, a nurse will connect the catheter to a fixed-rate portable elastometric pump (Easypump®, B Braun, Germany) filled with 300mL 0.2% SB at a default fixed rate of infusion of 5mL/hr. The syringe, catheter, pump and clamp will be covered by opaque black bags to conceal the drug appearance. The catheter will be removed on postoperative day 2.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Liposomal bupivacaine</intervention_name>
    <description>Single bolus injection 10mL 1.33% LB</description>
    <arm_group_label>Liposomal bupivacaine</arm_group_label>
    <other_name>Exparel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Standard bupivacaine</intervention_name>
    <description>Single bolus 10mL 0.25% SB + continuous 300mL 0.2% SB @5mL/hr</description>
    <arm_group_label>Standard bupivacaine CISB</arm_group_label>
    <other_name>Marcaine</other_name>
    <other_name>Sensorcaine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  ASA I-III&#xD;
&#xD;
          -  Age between 18 and 80&#xD;
&#xD;
          -  Isolated Proximal humeral fracture (AO Types 31.A1-3 and B1-3 or Neer 2/3 part or&#xD;
             greater tuberosity fracture equivalent)&#xD;
&#xD;
          -  Locking Plate fixation&#xD;
&#xD;
          -  Split deltoid minimal invasive approach&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Revision surgery&#xD;
&#xD;
          -  Impaired cognitive function (Abbreviated Mental Test Score (AMT score) &lt; 8)&#xD;
&#xD;
          -  4 part fractures&#xD;
&#xD;
          -  Poor surgical reduction quality&#xD;
&#xD;
          -  Unable to attend rehabilitation&#xD;
&#xD;
          -  Preexisting shoulder problems&#xD;
&#xD;
          -  Fracture fixation stability unable to tolerate early passive motion exercise&#xD;
&#xD;
          -  Use of implants other than a locking plate for fracture fixation&#xD;
&#xD;
          -  Activity of daily living is dependent on others&#xD;
&#xD;
          -  Polytrauma&#xD;
&#xD;
          -  Use of deltopectoral approach&#xD;
&#xD;
          -  Patient unable to follow post-operative rehabilitation protocol with early&#xD;
             mobilization&#xD;
&#xD;
          -  Allergy to amide local anaesthetics, paracetamol, non-steroidal anti-inflammatory&#xD;
             drugs (NSAIDS), opioids&#xD;
&#xD;
          -  Respiratory Disease with limited respiratory reserve&#xD;
&#xD;
          -  Cardiac Disease: Any degree of Heart Block, Heart Failure&#xD;
&#xD;
          -  Neurological: Any Seizure Disorder&#xD;
&#xD;
          -  Psychiatric illnesses affecting pain perception e.g. severe depression and anxiety&#xD;
             disorder&#xD;
&#xD;
          -  Alcohol or substance abuse&#xD;
&#xD;
          -  Chronic Pain, other than chronic knee pain&#xD;
&#xD;
          -  Daily use of strong opioids (morphine, fentanyl, hydromorphone, ketobemidone,&#xD;
             methadone, nicomorphine, oxycodone, or meperidine)&#xD;
&#xD;
          -  Impaired Renal Function (defined as preoperative eGFR &lt; 30ml /min /1.73 m2)&#xD;
&#xD;
          -  Impaired Hepatic Function&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Inability to use PCA&#xD;
&#xD;
          -  Patient refusal to ISB&#xD;
&#xD;
          -  Patient refusal to study&#xD;
&#xD;
          -  Patients do not understand Cantonese&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chi Wing Chan</last_name>
    <role>Principal Investigator</role>
    <affiliation>Queen Mary Hospital, Hong Kong</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Christian Xinshuo Fang</last_name>
    <role>Principal Investigator</role>
    <affiliation>Queen Mary Hospital, Hong Kong</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Chi Wing Chan</last_name>
    <phone>22551740</phone>
    <email>timmychancw@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Christian Xinshuo Fang</last_name>
    <phone>22554581</phone>
    <email>fangcx@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Queen Mary Hospital</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chi Wing Chan</last_name>
      <phone>22551740</phone>
      <email>timmychancw@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Chi Wing Chan</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christian Fang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Hong Kong</country>
  </location_countries>
  <reference>
    <citation>Hodgson SA, Mawson SJ, Stanley D. Rehabilitation after two-part fractures of the neck of the humerus. J Bone Joint Surg Br. 2003 Apr;85(3):419-22.</citation>
    <PMID>12729121</PMID>
  </reference>
  <reference>
    <citation>Vorobeichik L, Brull R, Bowry R, Laffey JG, Abdallah FW. Should continuous rather than single-injection interscalene block be routinely offered for major shoulder surgery? A meta-analysis of the analgesic and side-effects profiles. Br J Anaesth. 2018 Apr;120(4):679-692. doi: 10.1016/j.bja.2017.11.104. Epub 2018 Feb 13.</citation>
    <PMID>29576109</PMID>
  </reference>
  <reference>
    <citation>Malik O, Kaye AD, Kaye A, Belani K, Urman RD. Emerging roles of liposomal bupivacaine in anesthesia practice. J Anaesthesiol Clin Pharmacol. 2017 Apr-Jun;33(2):151-156. doi: 10.4103/joacp.JOACP_375_15. Review.</citation>
    <PMID>28781438</PMID>
  </reference>
  <reference>
    <citation>Sabesan VJ, Shahriar R, Petersen-Fitts GR, Whaley JD, Bou-Akl T, Sweet M, Milia M. A prospective randomized controlled trial to identify the optimal postoperative pain management in shoulder arthroplasty: liposomal bupivacaine versus continuous interscalene catheter. J Shoulder Elbow Surg. 2017 Oct;26(10):1810-1817. doi: 10.1016/j.jse.2017.06.044. Epub 2017 Aug 24.</citation>
    <PMID>28844420</PMID>
  </reference>
  <reference>
    <citation>Budge M, Orvets N, Shields E. Single-shot liposomal bupivacaine interscalene nerve block provides equivalent pain relief compared to continuous catheter interscalene nerve block in total shoulder arthroplasty. Seminars in Arthroplasty: JSES. 2020;30(4):285-90.</citation>
  </reference>
  <reference>
    <citation>Marino J, Scuderi G, Dowling O, Farquhar R, Freycinet B, Overdyk F. Periarticular Knee Injection With Liposomal Bupivacaine and Continuous Femoral Nerve Block for Postoperative Pain Management After Total Knee Arthroplasty: A Randomized Controlled Trial. J Arthroplasty. 2019 Mar;34(3):495-500. doi: 10.1016/j.arth.2018.11.025. Epub 2018 Nov 23.</citation>
    <PMID>30583813</PMID>
  </reference>
  <reference>
    <citation>Weller WJ, Azzam MG, Smith RA, Azar FM, Throckmorton TW. Liposomal Bupivacaine Mixture Has Similar Pain Relief and Significantly Fewer Complications at Less Cost Compared to Indwelling Interscalene Catheter in Total Shoulder Arthroplasty. J Arthroplasty. 2017 Nov;32(11):3557-3562. doi: 10.1016/j.arth.2017.03.017. Epub 2017 Mar 16.</citation>
    <PMID>28390888</PMID>
  </reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>January 21, 2021</study_first_submitted>
  <study_first_submitted_qc>October 19, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 20, 2021</study_first_posted>
  <last_update_submitted>October 19, 2021</last_update_submitted>
  <last_update_submitted_qc>October 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The University of Hong Kong</investigator_affiliation>
    <investigator_full_name>Dr. Chan Chi-Wing</investigator_full_name>
    <investigator_title>Honorary Clinical Associate Professor</investigator_title>
  </responsible_party>
  <keyword>interscalene nerve block</keyword>
  <keyword>shoulder surgery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fractures, Bone</mesh_term>
    <mesh_term>Humeral Fractures</mesh_term>
    <mesh_term>Shoulder Fractures</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bupivacaine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>De-identified dataset underlying results to be published as an appendix in final publication.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_time_frame>Aim to publish protocol and analysis plan in a peer-reviewed journal prior to recruitment completion</ipd_time_frame>
    <ipd_access_criteria>Additional information available upon reasonable request of the corresponding author.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

